Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 13/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.53 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4551083 | 0.89 | CASP3 (0.80) | CASP3NPSR1S1PR1HPGDSMN1; SMN2 | |
| SCHEMBL4552075 | 0.85 | CASP3 (1.00) | CASP3S1PR1 | |
| SCHEMBL4551085 | 0.81 | CASP3 (1.00) | CASP3S1PR1 | |
| SCHEMBL4552076 | 0.80 | CASP3 (1.00) | CASP3NPC1RAB9ANR1H4NPSR1 | |
| SCHEMBL13930792 | 0.79 | CASP3 (0.65) | CASP3NPC1RAB9ANR1H4NPSR1 | |
| SCHEMBL4552238 | 0.78 | CASP3 (1.00) | CASP3NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4421393 | 0.77 | CASP3 (0.78) | CASP3NPC1RAB9A | |
| SCHEMBL4552426 | 0.77 | CASP3 (0.62) | CASP3NPC1RAB9AMAPT | |
| SCHEMBL4552309 | 0.76 | CASP3 (1.00) | CASP3S1PR1 | |
| SCHEMBL4552897 | 0.76 | CASP3 (1.00) | CASP3S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154012-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2005-07-14 | — | — | US | claimed |
| CN-1638776-A | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs | CYTOVIA INC (US) | 2005-07-13 | — | — | CN | claimed |
| EP-1406632-A2 | SUBSTITUTED 3-ARYL-5-ARYL- 1,2,4]-OXADIAZOLES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-04-14 | — | — | EP | claimed |
| US-20030045546-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-03-06 | — | — | US | claimed |
| WO-2002100826-A2 | SUBSTITUTED 3-ARYL-5-ARYL-[1,2,4]-OXADIAZOLES AND ANALOGS | CYTOVIA, INC. (US) | 2002-12-19 | — | — | WO | claimed |
| EP-1618205-A4 | METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS | CYTOVIA INC (US) | 2009-04-08 | — | — | EP | disclosed |
| US-7435750-B2 | Method of using substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7041685-B2 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1618205-A2 | METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS | Cytovia, Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050154012-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2005-07-14 | — | — | US | disclosed |
| CN-1638776-A | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs | CYTOVIA INC (US) | 2005-07-13 | — | — | CN | disclosed |
| US-20050004005-A1 | Methods of treating diseases responsive to Induction of Apoptosis | CYTOVIA, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004094648-A2 | METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS | CYTOVIA, INC. ET AL. (US) | 2004-11-04 | — | — | WO | disclosed |
| EP-1406632-A2 | SUBSTITUTED 3-ARYL-5-ARYL- 1,2,4]-OXADIAZOLES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030045546-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-03-06 | — | — | US | disclosed |
| WO-2002100826-A2 | SUBSTITUTED 3-ARYL-5-ARYL-[1,2,4]-OXADIAZOLES AND ANALOGS | CYTOVIA, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004005-A1 | Methods of treating diseases responsive to Induction of Apoptosis | PDCD6IP, THUMPD1, CCAR2 | CASP3 90/4885NPC1 4341/4885RAB9A 3925/4885 |
| US-20030045546-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP1, API5 | CASP3 1/4885NPC1 3032/4885RAB9A 3776/4885 |
| US-20050154012-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP1, CASP4 | CASP3 1/4885NPC1 3327/4885RAB9A 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.